MiRagen Therapeutics raises $41M Series C funding to initiate clinical trials

BOULDER — Biopharmaceutical company miRagen Therapeutics Inc., announced on Tuesday that the company has raised a $41 million Series C funding round that will help the company advance its first two drug candidates to clinical trials later this year.

The move into human clinical trials marks a major milestone for the Boulder-based company, which was founded in 2007 and is focused on the discovery and development of innovative microRNA-targeting therapies for various diseases, including cancer, fibrosis and heart disease.

The new funding round comes just about a week after miRagen expanded to occupy the entirety of 6200 Lookout Road in Gunbarrel, where…